Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 11, 2007 Brian Lawler	Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely.
The Motley Fool April 29, 2008 Brian Lawler	So Pharmasset, So Good Early data hints at a promising hepatitis C treatment.
The Motley Fool March 31, 2008 Brian Lawler	A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
The Motley Fool October 31, 2007 Brian Lawler	The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note.
The Motley Fool October 24, 2007 Brian Lawler	Pharmasset on the Fast Track Hepatitis and HIV drug developer announced that its lead antihepatitis C compound has received fast-track status from the FDA. The decision is not fantastic news, but it could help. Investors, take note.
The Motley Fool April 3, 2008 Brian Lawler	Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug.
The Motley Fool December 14, 2006 Brian Lawler	Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days.
The Motley Fool October 30, 2006 Brian Lawler	Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data.
The Motley Fool January 8, 2008 Brian Lawler	InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool November 6, 2007 Brian Lawler	No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns?
The Motley Fool August 4, 2008 Brian Lawler	Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline.
The Motley Fool April 1, 2008 Brian Lawler	Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier.
The Motley Fool August 11, 2010 Brian Orelli	Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.
The Motley Fool October 31, 2011 Brian Orelli	Gunning for the Leaders Hepatitis C drugs take center stage.
The Motley Fool July 25, 2007 Brian Lawler	Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report.
The Motley Fool April 25, 2008 Brian Lawler	Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug.
The Motley Fool December 28, 2007 Brian Lawler	Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen.
The Motley Fool January 30, 2009 Brian Orelli	Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent.
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
The Motley Fool November 8, 2007 Brian Lawler	Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note.
The Motley Fool December 16, 2011 Brian Orelli	Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.
The Motley Fool June 3, 2011 Brian Orelli	Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool February 10, 2005 Charly Travers	Focus on the Pipeline Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
The Motley Fool January 9, 2012 Brian Orelli	3 Reasons Hep C Premiums Might Not Last Careful what you wish for.
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool April 17, 2008 Brian Lawler	The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.
The Motley Fool July 27, 2011 Brian Orelli	Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.
The Motley Fool April 19, 2005 Charly Travers	A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year.
The Motley Fool March 28, 2008 Brian Orelli	The Yin and Yang of Schering's Label Changes Schering gets a pair of label changes that have opposite effects for its hepatitis C drug.
Chemistry World January 11, 2012 Andrew Turley	BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection.
The Motley Fool May 18, 2011 Brian Orelli	If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship.
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
The Motley Fool September 26, 2007 Brian Orelli	Second-Line Isn't Second Best Schering-Plough gets a positive recommendation for its hepatitis C drugs as a second-line treatment in Europe.
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
The Motley Fool September 28, 2007 Brian Orelli	Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
Chemistry World August 20, 2009 Sarah Houlton	Testing times: predicting hep C response A finding by David Goldstein and his group at Duke University in the US may make it possible to predict which patients are likely to benefit from the drugs, and which will probably suffer the nasty side-effects without much chance of success.
The Motley Fool November 21, 2011 David Williamson	Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977.
The Motley Fool June 14, 2011 Brian Orelli	Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.
The Motley Fool January 31, 2008 Brian Lawler	Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention.
The Motley Fool November 21, 2011 David Williamson	Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved.
The Motley Fool July 27, 2011 Alexander Crawford	Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve?
The Motley Fool January 9, 2012 David Williamson	Inhibitex Is an Instant Double Some takeout rumors do come true.
The Motley Fool November 5, 2011 David Williamson	Inhibitex Investors: Why Shares Popped 115% Great results for INX-189 send shares skyward.